Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast.

In this episode Tim chats with Alison Coutts, executive chair of Memphasys (ASX:MEM).

Formerly known as NuSep, Memphasys has developed a device called Felix to separate the good sperm from the bad, for the purpose of in vitro fertilisation (IVF) procedures.

According to the company, current sperm selection methods are time consuming and can even result in DNA damage to the samples.

Memphasys is in the commercialisation stage and is targeting low-regulation markets including New Zealand, Japan and Canada.

While the company is initially focused on human facility, artificial insemination is widely used in the production animals sector, as well as for specialist horses. Memphasys is confident that Felix can be adapted for the animal market, which could well be bigger than human IVF.

So tune in to hear the pair discuss the commercialisation of the Felix and the year ahead.

On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.

Like to listen to podcasts through another app? Just search for The Health Kick Podcast with Tim Boreham and subscribe!